Medintech presents INTION S clinical results and AI steering stack at Korean GI meeting
The AMW Read
Korean medical-robot startup advances a motorized endoscope past multi-site clinical non-inferiority toward AI tip-steering modules—an incremental clinical-device update within healthcare AI, not a segment-wide shift.
Medintech presents INTION S clinical results and AI steering stack at Korean GI meeting
South Korean medical-robot startup Medintech showcased clinical data for its motorized endoscope INTION S and outlined AI autonomous-steering software at the Korean Pancreatic and Biliary Association's 2026 Young Leaders' Camp in Busan. Seoul National University Hospital gastroenterologist Ji-Gon Ryu presented a 2024 single-center, single-blind randomized non-inferiority trial of screening EGD in 178 adults, later published in Scientific Reports (2026, Vol. 16). The motorized system met non-inferiority versus conventional scopes on overall operability and reduced clinician-reported fatigue and workload, with no meaningful gaps in patient satisfaction or safety; image quality, field of view, and resolution still favored the incumbent hardware. A 2025 five-hospital randomized trial enrolled 320 patients across Seoul National University Hospital, Boramae, Bundang SNUH, Severance, and Dongguk University Ilsan Hospital, with 11 endoscopists assessing procedure time, operability, workload, satisfaction, and safety.
Motorizing tip control—replacing wheels and wires with precision motors and electrical signals—matters because it turns endoscope motion into a software-addressable surface. Imaging and lesion-detection AI have outpaced the mechanical control layer for years; Medintech is pairing the electrified handle with EndoTrack (lesion-following tip guidance) and EndoPilot (insertion-path steering assist), with stated plans to extend software to lesion sizing and therapy-path support. That is the clinical-device pattern where actuation hardware unlocks closed-loop assistance rather than vision overlays alone, while still sitting inside hospital procurement and medical-device evidence regimes.
For builders and investors in healthcare AI devices, the signal is evidence sequencing: multi-site operability and ergonomics data first, image-quality catch-up as an explicit follow-on, and AI modules presented as development-stage rather than cleared commercial claims. Distribution still runs through academic society channels and Korean tertiary hospitals tied to pan-government medical-device R&D programs—useful as a clinical-validation path, not yet a global commercial readout.